Trial reportEuropean heart journal2014
Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.
Trial report in European heart journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00888433 (Renal Denervation in Patients With Uncontrolled Hypertension), which is not on this map. Cited by 116 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Who cites it
116 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The Efficacy and Safety of Different Ways of Renal Denervation for Hypertension: A Systematic Review and Network Meta-Analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2025Pooled it
- A meta-analysis and review on the effectiveness and safety of renal denervation in managing heart failure with reduced ejection fraction.Renal failure · 2024Pooled it
- Renal denervation for resistant hypertension.The Cochrane database of systematic reviews · 2021Pooled it
- Account for Clinical Heterogeneity in Assessment of Catheter-based Renal Denervation among Resistant Hypertension Patients: Subgroup Meta-analysis.Chinese medical journal · 2017Pooled it
- Renal denervation for resistant hypertension.The Cochrane database of systematic reviews · 2017Pooled it
- Thirty-six-month results of laparoscopic-based renal denervation plus unilateral laparoscopic adrenalectomy for the treatment of patients with resistant hypertension caused by unilateral aldosterone-producing adenoma.Journal of clinical hypertension (Greenwich, Conn.) · 2021Trial
- Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial.Journal of the American Heart Association · 2017Trial
- Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry.European heart journal · 2017Trial
- Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.Journal of hypertension · 2016Trial
- Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial.Journal of hypertension · 2016Trial
- Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency.Cardiovascular revascularization medicine : including molecular interventionsTrial
- Renal Denervation in Cardiovascular Diseases: Mechanisms, Evidence, and Expanding Applications.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Review
- Renal Denervation in Asia: 2025 Asia Renal Denervation Consortium (ARDeC) Consensus Statement Endorsed by the Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network.Hypertension (Dallas, Tex. : 1979) · 2026Review
- Resistant hypertension: Epidemiology, mechanisms and contemporary therapeutic strategies.Heart international · 2026Review
- Clinical research progress of renal denervation for heart failure treatment: current evidence, controversies, and future directions.Frontiers in cardiovascular medicine · 2026Review
- Sodium-glucose co-transporter 2 inhibitor-induced increase in adenosine promotes lipolysis and weight reduction by activating reno-adipose autonomic neurocircuitry.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- The road to renal denervation for hypertension and beyond (HF): two decades of failed, succeeded, and to be determined.Heart failure reviews · 2025Review
- Article
- Clinical trials in neuromodulatory treatment of drug-resistant hypertension and the need for spinal cord stimulation trials: a PRISMA systematic review.Bioelectronic medicine · 2024Review
- Research status and frontiers of renal denervation for hypertension: a bibliometric analysis from 2004 to 2023.Journal of health, population, and nutrition · 2024Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe aim of this study was to determine long-term results of renal artery denervation for treatment of treatment-resistant hypertension in the SYMPLICITY HTN-2 study.
methodsSYMPLICITY HTN-2 randomized 106 subjects with treatment-resistant hypertension to renal denervation or medical therapy alone. At 6 months, 37 control subjects crossed over to renal denervation. Office blood pressure measurements, antihypertensive medication use, and safety events were followed every 6 months through 3 years.
resultsFollow-up was available at 36 months in 40 of 52 subjects in the initial renal denervation group and at 30 months in 30 of 37 subjects who crossed over and received renal denervation at 6 months. Baseline blood pressure was 184 ± 19/99 ± 16 mmHg in all treated subjects. At 30-month post-procedure, systolic blood pressure decreased 34 mmHg (95% CI: -40, -27, P < 0.01) and diastolic blood pressure decreased 13 mmHg (95% CI: -16, -10, P < 0.01). The systolic and diastolic blood pressure reduction at 36 months for the initial renal denervation group was -33 mmHg (95% CI: -40, -25, P < 0.01) and -14 mmHg (95% CI: -17, -10, P < 0.01), respectively. Procedural complications included one haematoma, and one renal artery dissection before energy delivery that was treated successfully. Later complications included two cases of acute renal failure, which fully resolved, 15 hypertensive events requiring hospitalization, and three deaths.
conclusionRenal denervation resulted in sustained lowering of blood pressure at 3 years in a selected population of subjects with severe, treatment-resistant hypertension without serious safety concerns. CLINICAL
trial registrationNCT00888433.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.